DoMark International Inc. (OTCBB:DOMK) reached up 17.67% in morning trading to $3.33 with 500K shares traded. DoMark International, Inc., through its wholly owned subsidiary, SolaWerks, Inc., is dedicated to revolutionizing the efficiency and capabilities of a new generation of mobile devices. They only acquire and develop energy-efficient technology poised to potentially generate tremendous profits. DoMark International Inc. (DOMK.OB) announced today that management of its wholly-owned subsidiary, SolaWerks, has confirmation from the manufacturer of the hot new “SolaPad” product that the first order of production units are being prepared for shipment. Management anticipates pre-orders for “SolaPad” will be accepted via the SolaWerks website by the middle of next week. Deliveries to pre-order customers are anticipated to begin during the 1st week of June.
Uroplasty, Inc. (Nasdaq:UPI) reached up 12.84% in morning trading to $3.78 with 500K shares traded. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Their primary focus is the commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers percutaneous tibial nerve stimulation for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. Uroplasty, Inc. (UPI) yesterday announced two new research and development initiatives to expand its commitment to using the Company's neuromodulation technology to treat voiding dysfunctions.
Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) (TSX:NTB) reached up 8.91% in morning trading to $3.79 with 750K shares traded. Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) (TSX:NTB.TO) reports today its consolidated financial results for the fiscal year ended February 29, 2012, announces corporate reorganization and the holding of an earning call. Fiscal year ended February 29, 2012 Financial Results: Nutraceutical revenues increased by 15% to a record $19,113,000, for the fiscal year ended February 29, 2012, up from $16,583,000 achieved during the corresponding period ended February 28, 2011; Net income from nutraceutical business improved by 136% and reached a net income of $2,384,000 for the fiscal year ended February 29, 2012, compared to a net income of $1,010,000 for the corresponding period ended February 28, 2011; EBITDA from nutraceutical business for the fiscal year ended February 29, 2012 reached $2,690,000, compared to$2,818,000 obtained during the corresponding period ended February 28, 2011.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
